Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABVC vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)

ABVC Overall Winner 6-Pillar Tally: ABVC 3 – 2 VVOS (1 Tie) Matrix Metrics: ABVC 8 – 0 VVOS

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ABVC carries a Unified Composite Score of 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABVC vs VVOS
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.87
-1.56% 1D
Market Cap $23.9M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.24β · 44% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $0.98 · SMA50: $1.01
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (ABVC 3 – 2 VVOS)

Columns: Metric · ABVC · VVOS
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.9x 0.1x
2. Growth & Scale ABVC
Revenue Growth (YoY) +104.5% +34.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $797,916 $21M
Market Cap $23.9M $1.9M
3. Profitability & Quality ABVC
Gross Margin 100.0% 61.9%
Operating Margin 0.0% -107.9%
Net Profit Margin 0.0% -121.8%
Return on Equity (ROE) -52.7% -8585.3%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$5.8M EBITDA -$21M EBITDA
Cash Flow Margin N/A -99.3% EBITDA Mgn
Net Cash / Leverage $0.50 Book/Sh · -52.7% ROE -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABVC (8) vs VVOS (0)
Institutional Metric ABVC VVOS Criterion Row Edge
Market Capitalization
Scale
$23.9M $1.9M Larger Scale ABVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+104.5% +34.9% Higher Growth ABVC
Operating Margin (TTM)
Profitability
0.0% -107.9% Higher Margin ABVC
Net Profit Margin
Profitability
0.0% -121.8% Higher Margin ABVC
Return on Equity (ROE)
Capital Efficiency
-52.7% -8585.3% Higher ROE ABVC
52-Week Range Position
Momentum
7% ($1–$3) 0% ($0–$3) Stronger Trend ABVC
Beta / 30D Volatility
Risk Regime
1.24β · 44% Vol 1.70β · 111% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite ABVC
Trailing 12M Revenue (USD)
Operating Scale
$797,916 $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.9x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.8M EBITDA ($0.50 Book/Sh · -52.7% ROE) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVC +41.97 pp
ABVC: -17.28% · VVOS: -59.25%
3M Horizon ABVC +83.62 pp
ABVC: +3.13% · VVOS: -80.49%
6M Horizon ABVC +67.14 pp
ABVC: -24.01% · VVOS: -91.15%
1Y Horizon ABVC +29.56 pp
ABVC: -68.15% · VVOS: -97.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs VVOS. Trailing 12-month operating profitability (ABVC 0.0% vs VVOS -107.9%) and valuation multiples (ABVC N/M vs VVOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M
VVOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.9%
Op. Margin-107.9%
ROE / Fwd P/E-8585.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABVC vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ABVC carries a Unified Composite Score of 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin). Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVC leads the Growth & Scale pillar: ABVC posts +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). On trailing 12-month operating scale, ABVC generates $797,916 in USD-normalized revenue versus $21M for VVOS. In operating R&D and SG&A reinvestment, ABVC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

VVOS screens cheaper on headline valuation multiples. ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVC (-52.7% ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.